Skye Bioscience said the Cohort Review Committee approved the second cohort of its CBeyond Part C expansion study for Nimacimab in obesity. The update indicates continued clinical progress for the biotech's lead program, but it is an incremental trial milestone rather than a late-stage efficacy or regulatory result. The news is positive for development momentum, though likely limited in immediate market impact.
Skye Bioscience said the Cohort Review Committee approved the second cohort of its CBeyond Part C expansion study for Nimacimab in obesity. The update indicates continued clinical progress for the biotech's lead program, but it is an incremental trial milestone rather than a late-stage efficacy or regulatory result. The news is positive for development momentum, though likely limited in immediate market impact.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
